Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4] Group 2: Legal Proceedings - A class action lawsuit has been filed against Metagenomi following the announcement on May 1, 2024, that the collaboration agreement with Moderna was mutually terminated [4] - Investors are encouraged to join the class action and can do so without any out-of-pocket fees through a contingency fee arrangement [1][2] Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked highly for securities class action settlements [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) investors of a class action representing investors that bought securities between February 9 and February 13, 2024, inclusive (the "Class Period"). Metagenomi investors have until November 25, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F ...

Group 1 - The Law Offices of Howard G. Smith announced a securities fraud class action lawsuit against Metagenomi, Inc. for investors with substantial losses since the company's IPO in February 2024 [1] - The lawsuit alleges that Metagenomi failed to disclose that its collaboration with Moderna would terminate in the immediate future, which misled investors regarding the company's business prospects [2] - Investors are encouraged to contact the law firm to discuss their legal rights and options regarding the class action [3]

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=106647&from=4 CLASS PERIOD: This lawsuit is on behal ...

Core Viewpoint - The article discusses a class action lawsuit against Metagenomi, Inc. following its IPO, highlighting the deadline for investors to file a lead plaintiff motion and the alleged misleading statements made by the company regarding its collaboration with Moderna [1][4]. Group 1: Company Overview - Metagenomi, Inc. conducted its IPO on February 13, 2024, selling approximately 6.25 million shares at $15 per share [3]. - Following the announcement of the termination of its collaboration with Moderna on May 1, 2024, Metagenomi's stock price dropped by $0.87, or 12.4%, closing at $6.17 per share on May 2, 2024 [3]. Group 2: Legal Proceedings - A class action lawsuit has been filed on behalf of investors who purchased Metagenomi securities during the IPO, with a deadline of November 25, 2024, to file a lead plaintiff motion [1][6]. - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, particularly regarding the collaboration with Moderna [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Metagenomi, Inc. due to alleged violations of federal securities laws related to misleading statements about its collaboration with Moderna, which has led to significant investor losses [3][4][5]. Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4]. - The company completed its initial public offering on February 13, 2024, selling 6.25 million shares at $15 per share [5]. Group 2: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 between February 9, 2024, and September 26, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Metagenomi, with a deadline of November 25, 2024, for investors to seek the role of lead plaintiff [1][6]. Group 3: Allegations and Impact - The complaint alleges that Metagenomi and its executives made false or misleading statements regarding their collaboration agreement with Moderna [3]. - Following the announcement of the termination of the collaboration agreement on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 per share within a day, indicating a negative market reaction [5].

Core Viewpoint - A class action lawsuit has been filed against Metagenomi, Inc. for allegedly misleading statements made during its IPO, particularly regarding its collaboration with Moderna, which was terminated shortly after the IPO [1][3]. Company Overview - Metagenomi, Inc. conducted its IPO on February 12, 2024, selling approximately 6.25 million shares at $15 per share [2]. - The company positioned itself as a "genetic medicines company" with a longstanding relationship with Moderna, a leading Covid-19 vaccine company [3]. Recent Developments - On May 1, 2024, Metagenomi announced the termination of its collaboration with Moderna, leading to a significant drop in its share price from $7.04 to $6.17, a decline of $0.87 or 12.4% [2]. Legal Proceedings - Investors who acquired Metagenomi securities during the class period from February 9, 2024, to May 1, 2024, have until November 25, 2024, to apply to be appointed as lead plaintiff in the lawsuit [1].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Metagenomi, Inc. regarding a class action lawsuit related to the company's initial public offering and subsequent termination of its collaboration with Moderna [1][3]. Group 1: Company Overview - Metagenomi, Inc. is characterized as a "genetic medicines company" that had a significant partnership with Moderna, which was highlighted during its initial public offering [3]. - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [3]. Group 2: Allegations and Impact - The lawsuit arises from allegations that Metagenomi misled investors about its collaboration with Moderna, which was a critical aspect of its business model [3]. - Following the announcement of the termination of the collaboration on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 within a day, indicating a significant market reaction to the news [3]. Group 3: Legal Proceedings - The class action lawsuit is on behalf of shareholders who purchased stock during the IPO period from February 9 to 13, 2024 [2]. - Shareholders are encouraged to register for the class action by November 25, 2024, to potentially become lead plaintiffs and to receive updates on the case [4].

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between Februa ...

Core Viewpoint - A class action securities lawsuit has been filed against Metagenomi, Inc. due to alleged securities fraud affecting investors who purchased shares during its initial public offering in February 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who bought shares based on Metagenomi's registration statement during its IPO held from February 9 to 13, 2024 [2]. - The complaint highlights that Metagenomi presented itself as a "genetic medicines company" with a significant partnership with Moderna, which was a key aspect of its business model [3]. - Metagenomi completed its IPO by selling 6.25 million shares at $15 per share, but the partnership with Moderna was terminated less than three months later on May 1, 2024, leading to a decline in stock price from $7.04 to $6.17 per share [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until November 25, 2024, to request to be appointed as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].